Calls

Ebola Survivor Data

Request for proposals: Compilation of Ebola Survivor Data and Literature

 

The 2014-15 Ebola outbreak in West Africa was a galvanizing event for the world which led to the formation of CEPI. At the time of the outbreak a handful of vaccine candidates were in the pipeline, and while data on safety and effectiveness of the Merck VSV vaccine was gained from several clinical trials conducted in 2015-16, no Ebola vaccine is yet licensed. Because the human response to vaccine is different than the response to natural infection, and the non-human primate model does not mirror the human response, CEPI is seeking to further support the scientific underpinning of Ebola vaccine development by helping animal model developers, vaccine developers, and regulators better understand and collate what is known about the human immune response.

 

Goals of this effort are: 1) a succinct, easily accessible summary, along with presentation of underlying data, regarding what is known about the human immune response to Ebola virus infection and vaccination with Ebola vaccine candidates 2) use of this data to develop additional animal models or correlates of protection that could be used by regulators in assessing the likely safety and immunogenicity of vaccine candidates.

 

Requirements

 

CEPI is seeking the following:

 

  1. A thorough review of published and unpublished data on the immune responses (in humans and animals) to Ebola virus infection and to vaccination with Ebola virus vaccine candidates, including both cellular and humoral immunity in individuals who did and did not survive. The goal of this review is to guide further development of non-human primate challenge models to enable them to better mimic human infection, and to identify other potential correlates of immunity or protection.
  2. Identification of investigators or sites that may have stored samples of serum or blood products that could be further analyzed as part of a CEPI-funded research consortium if potential new correlates of immunity or protection were identified. Information regarding: number and volume of specimens, characteristics of patients they were derived from, date of diagnosis and specimen collection, specimen processing and storage conditions, underlying comorbid conditions (e.g. malaria, HIV), age, pregnancy status and location of specimens should be compiled to the extent possible. For specimens collected from vaccinated individuals, also include what vaccine was used, in what clinical trial it was administered, what subject population it was administered to, how the immune response was evaluated, and what assay was used.
  3. Review the report from the Ebola vaccine regulatory science meeting held on March 22, 2017, linked here to identify which research gaps listed in the report have now been filled and by whom; and which research gaps still remain: http://cepi.net/sites/default/files/Meeting%20report_Ebola%20regulatory%20scientific%20meeting_FINAL.pdf

 

CEPI expects that the awardee will be able to identify most, if not all, of the investigators with relevant data and specimens, both published and unpublished. Applicants should indicate their methods for doing so. CEPI does NOT expect the awardee to perform any laboratory analyses of samples.

 

Bidder Qualifications

 

  • To be considered for a contract award under this tender, all tenders must meet the following criteria:
  • Experience in the relevant discipline with demonstrable technical capabilities and experience.
  • Documented experience in at least two similar types of projects and settings. Documented capabilities in terms of resource and time management.
  • Conduct efficient, productive and diplomatic communication with relevant internal and external stakeholders.
  • Professional level of spoken and written English.

Please note that as part of our assessment we may ask tenderers to provide references from clients you have worked with to validate your experience in similar work. Deadline for submission is 5:00pm EDT on Friday, November 2, 2018.

Proposals received after the deadline will not be considered. Costs for the preparation of proposals will not be refunded.

Electronic copies of your proposals should be sent to: Shannon.Quinlan@cepi.net in PDF format.

Request for proposals: Compilation of Ebola Survivor Data and Literature

Download full details on this request for proposals here.

PDF FORMAT - 452KB

Download

Lassa epidemiological studies

Responses to CEPI's call for expressions of interest into conducting epidemiological studies of Lassa fever in West Africa. 

We recently announced plans to provide grants for epidemiological studies of Lassa virus that will inform future trial design, endpoints, and site selection for Lassa-vaccine development.

We invited research groups to express their interest in performing such studies. The expression of interest serves as a prequalification to apply for funding through a subsequent “request for proposals” on epidemiological studies of Lassa virus.

Applicants will be informed of selection results by October 2018. Applicants selected through this expression of interest will receive “prequalification” to apply for funding through a formal request for proposals (RfP) to be launched at the end of 2018. 

“Prequalified” applicants will be expected to participate in a workshop in Q4 2018 to provide input on harmonising the core study protocol that CEPI will use for the RfP.

CfP2

Responses to CEPI's second call for proposals

On 1st September 2017, CEPI launched its Second Call for Proposals (CfP) on Vaccine platform technologies to promote the objective of developing development of real time response capabilities to novel emerging threats, and immunize at-risk populations against emerging infectious diseases, potentially resulting in great public health impact by rapidly limiting or ending outbreaks.

In response to this Call for Proposals, the Secretariat received over 35 applications by the deadline of 17 October, with a broad diversity displayed in the vaccine platform technologies being proposed, including both novel concepts and established technologies. All eligible submissions are now being evaluated, and shortlisted applicants will be notified in December to submit detailed proposals in early 2018.

Similar to our previous call, applicants and their partners are from North America, South America, Europe, Africa, Asia and Australia, representing academic institutions, biotechs, large pharmaceutical companies and Product Development Partnerships.

More information

Work on Ebola

The "Ebola vaccines regulatory scientific meeting" enabled us to look into future regulatory scientific research areas which will be further refined and taken forward in smaller task forces. Updates on how we will proceed the work on Ebola will be published on our website and Newsletter.
The summary report can be found here.

Past Calls

CfP1 - Lassa, MERS and Nipah

CfP2 - Platform technologies

RfI - Rapid Response Platform Technologies for Epidemic Preparedness

Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks

Request for proposals: biological standards to support and accelerate Lassa fever vaccine development